Year All202620252024202320222021202020192018201720162015201420122011 Nov 30, 2021 Ardelyx Launching IBSRELA® Second Quarter of 2022 Nov 12, 2021 Ardelyx Reports Third Quarter 2021 Financial Results Nov 11, 2021 Ardelyx to Present at the Jefferies London Healthcare Conference Nov 5, 2021 Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021 Nov 4, 2021 Ardelyx to Pursue Formal Dispute Resolution for Tenapanor Oct 29, 2021 Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021 Oct 13, 2021 Ardelyx Provides Corporate Update Following Type A Meeting with FDA Sep 3, 2021 Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial Aug 13, 2021 Ardelyx Reports Second Quarter 2021 Financial Results Jul 29, 2021 Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis